OptiBiotix Health PLC License agreement for LPLDL® (0835Y)
07 Mayo 2019 - 01:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0835Y
OptiBiotix Health PLC
07 May 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
License agreement for LP(LDL) (R) in personalised nutrition
applications
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its fully-owned subsidiary ProBiotix
Health Ltd., has signed a license agreement with Instituto Español
de Nutrición Personalizada, S.A. ("IENP") for the use of
Lactobacillus plantarum ("LP(LDL) (R)") in personalised food
supplements in Spain.
The agreement grants IENP non-exclusive rights to manufacture
and market food supplements containing OptiBiotix's cholesterol and
blood pressure-reducing probiotic strain LP(LDL) (R) in Spain for a
period of three years. IENP is the precision nutrition branch of
CAPSA Food, one of the largest food conglomerates in Spain, owner
of leading dairy brands such as Central Lechera Asturiana and
Larsa, with annual revenues of over EUR700m. In 2017, they were
awarded 'Leading company in the Food Sector' with the ORO +500 SEAL
of European Excellence and the Reptrak first prize for the company
with the best reputation in Spain by the Reputation Institute (see
https://www.capsafood.com/company/awards)
IENP have developed an innovative genomic test to analyse the
gut microbiome, the bacteria living in the intestine, to detect
imbalances which may potentially lead to different health
conditions. Based on results, customers are placed on different,
targeted food supplement regimens to take their microbiome
composition back to healthy. IENP have developed COL-15, a
microbiome-modulating food supplement commercialised under the
"39ytú" brand. IENP will use their extensive network to market the
product in supermarkets, department stores, pharmacies, and online
across Spain.
Personalised nutrition is a nascent field which holds the
promise to revolutionise the way food, health and wellness are
conceived. According to Reseach And Markets (2018), the global
market for personalised nutrition is expected to grow by CAGR ca.
10% to USD$50bn by 2025, with food supplements its fastest-growing
segment.
Dr. Luis Gosálbez, Business Development Director of OptiBiotix,
commented: "We are delighted to enter the field of personalised and
precision nutrition, one of the fastest-growing and highest-value
sectors within the food industry. We chose IENP due to its industry
reputation, decades of experience in the Spanish food market, and
its ability to rapidly launch products and build sales. Within two
years of launch, we now have products being sold by numerous
partners in over 30 countries around the world. This builds
revenues and increases the value of our trademarked and patented
assets, like LP(LDL) (R), as it grows into a global brand. We see
this agreement as another step to growing revenues, market
presence, and brand value of LP(LDL) (R), the 'Intel' inside a wide
range of products in consumer and pharmaceutical markets around the
world."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance) Tel: 020 7220 0500
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRBSGDURBGBGCX
(END) Dow Jones Newswires
May 07, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024